Choose Your Country or Region

Balixafortide (POL6326)

Name: Balixafortide (POL6326)
Brand: Selleck Chemicals
SKU: S9725
Rating: 5 (1 reviews)

Catalog No.S9725 Purity:98.69%

Balixafortide (POL6326) is an orally bioavailable peptidic CXC chemokine receptor 4 (CXCR4) antagonist.

Balixafortide (POL6326) Chemical Structure

CAS No. 1051366-32-5

Purity & Quality Control

Batch: S972501 Water]100 mg/mL]false]]]false]]]false Purity: 98.69%

98.69

Balixafortide (POL6326) Related Products

Related Targets	CXCR1 CXCR2 CXCR4 CXCR3	Click to Expand
Related Products	SB225002 WZ811 Reparixin (Repertaxin) LIT-927 Navarixin (SCH-527123) UNBS5162 LY2510924 AZD5069 AMD3465 hexahydrobromide AMG 487 SX-682 Danirixin (GSK1325756) MSX-122	Click to Expand
Related Compound Libraries	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Highly Selective Inhibitor Library	Click to Expand

Signaling Pathway

CXCR Signaling Pathway

Biological Activity

Description

Balixafortide (POL6326) is an orally bioavailable peptidic CXC chemokine receptor 4 (CXCR4) antagonist.

Targets

CXCR4 ^[1]

In Vivo
In vivo	POL6326 enhances systolic function in a porcine closed-chest model of reperfused acute MI. POL6326 mobilizes Treg cells, enhances Treg cell recruitment to the infarct, attenuates tumor necrosis factor expression in monocytes and macrophages in the infarcted region, enhances infarct border-zone capillarization, reduces infarct scar size, and attenuates LV remodeling and systolic dysfunction in mice.^[2]
Animal Research	Animal Models	C57BL/6NCrl wild-type (WT) mice, domestic (DanBred hybrid) female pigs
	Dosages	8 mg/kg, 3 mg/kg
	Administration	IV

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04826016	Withdrawn	Advanced Breast Cancer	MedSIR	March 16 2022	Phase 1\|Phase 2
NCT01905475	Completed	Large Reperfused ST-Elevation Myocardial Infarction	Polyphor Ltd.	July 2013	Phase 2
NCT01837095	Completed	Metastatic Breast Cancer	Polyphor Ltd.	June 2013	Phase 1
NCT01841476	Completed	Healthy	Polyphor Ltd.	February 2012	Phase 1
NCT01105403	Completed	Multiple Myeloma	Polyphor Ltd.	April 2009	Phase 2

References

Chemical Information & Solubility

Molecular Weight	1864.11	Formula	C₈₄H₁₁₈N₂₄O₂₁S₂
CAS No.	1051366-32-5	SDF	--
Smiles	CC1NNC(CC2=CN=C[NH]2)C(=O)NC(CC3=CC=C(O)C=C3)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CCCCN)C(=O)NC(CCC(N)=O)C(=O)NC(CC6=CC=C(O)C=C6)C(=O)NC7CSSCC(NC1=O)C(=O)NC(CO)C(=O)NC(C)C(=O)N8CCCC8C(=O)NC(CCN)C(=O)NC(CCCNC(N)=N)C(=O)C(=O)C(CC9=CC=C(O)C=C9)NC7=O
Storage (From the date of receipt)	3 years -20°C powder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years -20°C powder		1 month-20°Cin solvent

In vitro
Batch:

Water : 100 mg/mL

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):